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Smooth muscle cells (SMC) maintained in high glucose are more responsive to IGF-I than those in normal glucose. There is
signiﬁcantly more thrombospondin-1 (TSP-1) in extracellular matrix surrounding SMC grown in 25 mM glucose. In this study
we investigated 1) the mechanism by which glucose regulates TSP-1 levels and 2) the mechanism by which TS-1 enhances IGF-I
signaling.TheadditionofTSP-1toprimarySMCwassuﬃcienttoenhanceIGF-Iresponsivenessinnormalglucose.ReducingTSP-
1proteinlevelsinhibitedIGF-IsignalinginSMCmaintainedinhighglucose.WedeterminedthatTSP-1protectedIAP/CD47from
cleavage and thereby facilitated its association with SHP substrate-1 (SHPS-1). We have shown previously that the hyperglycemia
induced protection of IAP from cleavage is an important component of the ability of hyperglycemia to enhance IGF-I signaling.
Furthermore we determined that TSP-1 also enhanced phosphorylation of the β3 subunit of the αVβ3 integrin, another molecular
event that we have shown are critical for SMC response to IGF-I in high glucose. Our studies also revealed that the diﬀerence in
the amount of TSP-1 in the two diﬀerent glucose conditions was due, at least in part, to a diﬀerence in the cellular uptake and
degradation of TSP-1.
1.Introduction
Atherosclerosis occurs more frequently in patients in which
the vascular environment has been disrupted due to changes
in the metabolic (e.g., diabetes) or mechanical (e.g., hyper-
tension) environment. Insulin-like growth factor-I (IGF-
I) stimulates smooth muscle cell (SMC) proliferation and
has been implicated in the lesion progression [1–3]. When
SMCs are grown in hyperglycemic conditions, they are
more responsive to IGF-I than those grown in normo-
glycemic conditions. We have determined that, under these
conditions, the enhanced proliferative response of SMC
to IGF-I is dependent upon two variables. First, the sig-
niﬁcant increase in the amount of three αVβ3 ligands
including TSP-1, osteopontin, and vitronectin (Vn) within
the extracellular matrix (ECM) surrounding SMC grown in
25mM glucose compared with those grown in 5mM [4].
A second important variable is the increase in association
between the extracellular domains of CD47/IAP (integrin
associated protein) and SHP substrate 1 (SHPS-1) which
is required for IGF-I responsiveness of SMC [5, 6]. The
increase in association between the two proteins is due to
an increase in intact CD47/IAP as a result of hyperglycemia
induced protection from matrix-metalloprotease-2 (MMP-
2) mediated cleavage [6].
TSP-1 is a ligand for CD47/IAP [7] and enhances
IGF-I signaling in SMC [8]. When aortic extracts from
hyperglycemic mice were compared with normo-glycemic
mice there was a signiﬁcant increase in TSP-1 and TSP-
1 binding to CD47/IAP [9]. Associated with this was an
enhanced proliferative response to IGF-I. These current
studies were undertaken to determine how TSP-1 functions
to modulate the SMC response to IGF-I and the mechanisms
by which hyperglycemia regulates TSP-1 protein.
2.ExperimentalProcedures
2.1. Details Provided in Supplemental Information
2.1.1. Porcine SMC (SMC). SMCs were isolated and main-
tained as we have described previously [4, 6].2 Experimental Diabetes Research
2.1.2. Preparation of Aorta from Normal and Hyperglycemic
Pigs. Male Yorkshire pigs (n = 8) were purchased from
Clemson University. Animals that were 2 months of age
were utilized. They were maintained according to the Guide
for care of laboratory animals (NIH publication #85-23).
Pigs on a high fat diet were infused with streptozotocin
(STZ: 50mg/kg/day) for 3 days. Mean fasting blood glucose
rose from 81 ± 11 to 360 ± 123mg/dL 7 days after the
infusion. Insulin (27 ± 12 Units) was administered daily to
the diabetic animals. Control animals gained 112 ± 5lbs
and hyperglycemic animals gained 77.5 ± 8lbs during the
course of the study. Three and a half months later the
animalswereeuthanized.Femoralarterieswerecollectedand
homogenized in modiﬁed RIPA [10].
2.1.3. RNA Interference (RNAi). Lentivirus containing the
pLenti6/BLOCK-iTDESTvectors+TSP-1orscrambledcon-
trol RNAi constructs was produced in 293FT cells and SMCs
were transduced [11]. Following selection, (growth medium
containing 4μg/mL blasticidin) the cultures were grown to
conﬂuency and reduction in TSP-1 protein conﬁrmed by
western immunoblotting.
2.1.4. Cell Proliferation. The increase in cell number stimu-
lated by IGF-I was determined as we have described previ-
ously [4].
2.1.5. Cell Treatments. SMCs were plated in high (25mM;
H) or normal (5mM; N)-growth medium (GM) and grown
for 24–120 hours. Conﬂuent monolayers were rinsed three
timeswithHorN-serum-freemedium(SFM)andincubated
overnight (16-17 hours) in SFM prior to the addition
of inhibitors, vehicle peptides and/or IGF-I (50ng/mL).
Baﬁlomycin A and Cathepsin inhibitor I were reconstituted
in ethanol and used at 100nM. TSP-1, 4N1K, and 4NGG
were prepared in phosphate buﬀered saline (PBS) and used
at 1μg/mL.
2.1.6. Extracellular Matrix (ECM) Isolation. ECM was pre-
pared as we have described previously [12].
2.1.7. Cell Membrane Preparation. Cell membranes were
prepared as we have described previously [13].
2.1.8. Real-Time PCR Analysis of TS-1 mRNA. Total RNA
was harvested using the Qiagen RNAeasy kit. cDNA was
made using 1μg of RNA (High Capacity cDNA Reverse
Transcription Kit; Applied Biosystems Foster City, CA).
Real-Time PCR reactions were set up using the TaqMan
Gene Assay kit and porcine TSP-1 (ABI Catalog number:
SS03373876 m1 THBS1) primer probe sets. Reactions were
performed in quadruplicate. ABI SDS 2.2.2 software was
used to determine relative amounts of RNA.
2.1.9. Protein Estimation and Visualization. Protein concen-
trations were determined using a BCA protein assay kit
(Pierce, Rockford IL). All samples were loaded on the gel
at the same concentration of total protein. Proteins were
visualized using immunoblotting as we have previously
described [8].
2.1.10. Statistical Analysis. Chemiluminescent images ob-
tainedwerescannedusingaDuoScanT1200(AGFABrussels,
Belgium) and band intensities of the scanned images were
analyzed using NIH Image, version 1.61. The Student’s t test
was used to compare diﬀerences between treatments. The
results that are shown in all experiments are representative
of at least three separate experiments.
3. Results
3.1. Correlation between TSP-1 Levels and Levels of Intact
IAP. Consistent with our previous observation [4] there was
signiﬁcantly more (14 ± 1.6f o l d[ m e a n± SEM, n = 3,
P<. 005]) TSP-1 associated with the cell membrane of
SMC maintained in high glucose conditions compared with
those maintained in normal (Figure 1(a) top panel). We
determined that there was signiﬁcantly more TSP-1 (3.7 ±
0. 7f o l d[ m e a n± SEM, n = 3, P<. 005]) deposited in
the ECM of SMC maintained in medium containing high
compared with normal glucose (Figure 1(a) second panel).
There was no signiﬁcant diﬀerence in the amount of TSP-
1 that was detected in the conditioned medium (Figure 1(a)
third panel).
Since TSP-1 is a ligand for CD47/IAP [7] we determined
whether the lack of TSP-1 in normal glucose conditions may
playaroleintheproteolysisofCD47/IAPbyaddingTSP-1to
SMC maintained in normal glucose. Using an antibody that
speciﬁcally detects the intact, but not proteolytically cleaved
CD47/IAP [6], there was signiﬁcantly less intact IAP in SMC
maintainedinnormalglucosecomparedwithhigh.Addition
of TSP-1 resulted in a signiﬁcant increase in the amount of
intact CD47/IAP that could be detected in SMC maintained
innormalglucose,suchthatthelevelofintactCD47/IAPwas
equivalent to that seen in SMC maintained in high glucose
(Figure 1(b)).
To demonstrate that a similar increase in TSP-1 and
CD47/IAP levels occurs in vivo in response to hyperglycemia
we examined the amount of TSP-1 and IAP in aorta
homogenates from hyperglycemic and control pigs. Consis-
tent with our previous ﬁndings in mice [9] we determined
thattherewasasigniﬁcant(2±0.1fold[mean±SEM,n = 3,
P<. 005]) increase in the amount of TSP-1 that was present
in the aorta from the hyperglycemic pigs. This was associated
with a signiﬁcant (2.1 ±0.1[ m e a n± SEM, n = 3, P<. 005])
increase in the amount of intact CD47/IAP that could be
detected (Figure 1(c)). There was no signiﬁcant diﬀerence
in the amount of IGF-I receptor (IGF-IR). While the aorta
homogenates contain a mixture of cells including, SMC, the
data supports our in vitro ﬁndings that hyperglycemia is
associated with an increase in TSP-1 and CD47/IAP.
To determine whether TSP-1 binding to CD47/IAP
playedaroleintheincreaseinintactCD47/IAP,weexamined
the eﬀect of small synthetic peptide (4N1K) homologous to
the CD47/IAP binding site of TSP-1 and a control peptideExperimental Diabetes Research 3
IB: TSP-1
IB: TSP-1
IB: TSP-1
IB: β3
52 5 m M g l u c o s e
Membrane
extract
Extracellular
matrix
Conditioned
medium
Membrane
extract
(a)
0
2500
5000
7500
10000
12500
15000
A
r
b
i
t
r
a
r
y
s
c
a
n
u
n
i
t
s
TSP-1
25 5 mM glucose
IB: IAP
IB: SHPS-1
− + − +
− + − + TSP-1
∗∗∗
(b)
0
1
2
3
A
r
b
i
t
r
a
r
y
s
c
a
n
u
n
i
t
s
×104
TSP-1 IAP
IB: TSP-1
IB: IAP
IB: IGF-IR
STZ CON
STZ CON STZ CON
∗∗
∗∗
(c)
0
0.5
1
1.5 25 5 mM glucose
Fold increase
in IAP compared
with 25mM glucose
25 5 mM glucose
IB: IAP
IB: SHPS-1
−
−
+
−
−
+
−
−
+
−
−
+
4N1K
4NGG
+4N1K +4N1K
(d)
Figure 1: TSP-1 levels correlate with the level of intact IAP in SMC. (a) SMC were grown to conﬂuency in DMEM containing 5 or 25mM
glucose and then incubated overnight in SFM with the appropriate level of glucose. Extracellular matrix, membrane extract or conditioned
medium was harvested as described in the methods. Equal amounts of protein were immunoblotted (IB) with either an anti-TSP-1 or β3
antibody. (b) SMC were grown and incubated overnight in SFM as described for (a). The following day the incubation was continued for a
further 6 hours after the addition (+) of TSP-1, (1μg/mL). The graphs show arbitrary scanning units derived from the immunoblots with
the anti-IAP antibody from three independent experiments. ∗∗∗P<. 005 when the level of IAP in the presence of TSP-1 is compared to SFM
alone. (c) Equal amount of protein from the homogenates of aorta from normal (Con) and hyperglycemic (STZ) pigs were separated by SDS
PAGE and the level of TSP-1, IAP and the IGF-IR determined by western immunoblotting (IB). The graphs shows show arbitrary scanning
units derived from the immunoblots with the anti-TSP-1 or IAP antibody, as labeled, from three independent experiments. ∗∗P<. 01 when
the level of TSP-1/IAP from the STZ animals is compared with control. (d) SMC were grown and incubated overnight in SFM as described
for (a). The following day the incubation was continued for a further 6 hours after the addition (+) of 4N1K or 4N1G, (1μg/mL). The graph
shows the fold diﬀerence in IAP levels compared with the level derived from SMC incubated in 25mM glucose using arbitrary scanning
units from the immunoblots with the anti-IAP antibody from three independent experiments.
4NGG [8]. Addition of 4N1K but not 4NGG resulted in a
signiﬁcant (10 ± [mean ± SEM, n = 3, P<. 005]) increase
in the amount of intact CD47/IAP that could be detected in
SMC maintained in normal glucose (Figure 1(d)) such that
the amount of intact CD47/IAP was equivalent to that seen
in SMC cultured in high glucose as shown in the graph in
Figure 1(d).
3.2. Addition of the IAP Binding Site of TSP-1 Enhances IGF-
I Signaling in SMC in Normal Glucose. CD47/IAP binding
to SHPS-1 is a prerequisite for IGF-I stimulated SHPS-1
phosphorylation which in turn is required to recruit and
facilitate the phosphorylation of the adaptor protein Shc
[11] and downstream signaling pathways [11, 14] leading to
increases in cell proliferation and migration [15].
Addition of4N1K, butnot4NGG, toSMCmaintained in
normal glucose containing medium resulted in a signiﬁcant
(3.3 ± 0.1 fold [mean ± SEM, n = 3, P<. 005]) increase in
CD47/IAP association with SHPS-1 (Figure 2(a)). In normal
glucose conditions IGF-I cannot stimulate an increase in
SHPS-1 phosphorylation [6]. Following treatment with
4N1K there was a signiﬁcant (8 ± 1.4f o l d[ m e a n± SEM,4 Experimental Diabetes Research
n = 3, P<. 005]) increase in SHPS-1 phosphorylation and
a signiﬁcant (6.2 ± 1.1[ m e a n± SEM, n = 3, P<. 005])
fold increase in Shc phosphorylation in response to IGF-I
(Figure 2(b)). Addition of 4NGG had no eﬀect.
In some experiments, we observe a basal increase in
SHPS-1 phosphorylation however, it is not associated with
any increase in Shc phosphorylation or downstream signal-
ing (Figure 2(b)) presumably due to the lack of increase in
SHPS-1 phosphorylation in response to IGF-I.
There was a signiﬁcant (12 ± 3f o l d[ m e a n± SEM,
n = 3, P<. 005]) increase in pERK1/2 phosphorylation in
response to IGF-I which we have shown is required for IGF-I
stimulated SMC proliferation (Figure 2(c)).
3.3. Reducing TS-1 Protein Using RNA Interference (RNAi)
Decreases Intact IAP and Inhibits IGF-I Signaling. In SMC
expressing the TSP-1 RNAi construct, maintained in high
glucose, there was a signiﬁcant (3.5±0.5f o l d[ m e a n± SEM,
n = 3, P<. 005]) decrease in TSP-1 protein in the ECM
compared with SMC expressing a scrambled RNAi construct
(Figure 3(a) top panel). There was a signiﬁcant (7.8 ± 1.1
fold [mean ± SEM, n = 3, P<. 005]) decrease in the
amountofintactCD47/IAPthatcouldbedetectedcompared
with control (Figure 3(b) second panel). There was also a
signiﬁcant (2.6 ± 0.3f o l d[ m e a n± SEM, n = 3, P<. 005])
decrease in CD47/IAP association with SHPS-1 (Figure 3(b)
third panel).
In SMC expressing the TSP-1 RNAi construct IGF-
I stimulation of SHPS-1 and Shc phosphorylation was
completely inhibited (Figure 3(b)). This was associated with
an inhibition in IGF-I stimulated ERK1/2 phosphorylation
(Figure 3(c)).SMCexpressingthescrambledRNAiconstruct
responded to IGF-I with signiﬁcant increases in SHPS-1, Shc
and ERK1/2 phosphorylation (Figures 3(b) and 3(c)).
3.4.AdditionofRecombinantTSP-1totheTS-1RNAiCultures
Restored IGF-I Signaling. We examined the eﬀect of adding
the4N1KpeptidetotheTSP-1RNAiculturesinhighglucose.
Addition of 4N1K restored the amount of intact CD47/IAP
that could be detected to the same level as seen in control
cultures. This was associated with a corresponding increase
in IAP association with SHPS-1 (Figure 4(a)).
Addition of 4N1K facilitated a 2.5 ± 0.3 fold increase
in SHPS-1 in response to IGF-I in TSP-1 RNAi cultures
[mean ± SEM, n = 3, P<. 005] (Figure 4(b)). The increase
in SHPS-1 association in the presence of 4N1K was also
associated with a signiﬁcant 3.2 ± 0.1 fold increase in Shc
phosphorylation in response to IGF-I [mean ± SEM, n = 3,
P<. 005]. Consistent with the lack of signaling in response
to IGF-I, TSP-1 RNAi cultures demonstrated no signiﬁcant
increase in cell number in response to IGF-I (Figure 4(c)).
However,whenTSP-1RNAiculturesweretreatedwith4N1K
there was a signiﬁcant increase in cell number in response to
IGF-I equivalent to the response noted in control cultures
(Figure 4(c)).
3.5. TS-1 Regulation of β3 Phosphorylation. Our previous
studies have demonstrated the importance of the αVβ3
integrin in regulating IGF-I signaling responses of SMC in
high glucose conditions [4]. CD47/IAP was initially isolated
through its association with αVβ3 and has been shown by
us and others to increase αVβ3 ligand binding [16]. Ligand
binding to αVβ3 regulates β3 phosphorylation which we
have shown is critical for subsequent downstream signaling
in response to IGF-I [17]. The TSP-1 RNAi cultures (in
high glucose) had a signiﬁcant (60 ± 9% [mean ± SEM,
n = 3, P<. 005]) reduction in β3 phosphorylation
compared with control cultures (Figure 5(a) top panel).
Therewasnosigniﬁcantdiﬀerencein β3binding toitsligand
Vn to account for this reduction in β3 phosphorylation
(Figure 5(a) second panel). However, there was a signiﬁcant
(83 ± 6.4% [mean ± SEM, n = 3, P<. 005]) reduction in
IAP association with β3 in cells with reduced TSP-1 protein
(Figure 5(a) third panel).
The addition of 4N1K, but not 4NGG, resulted in a
signiﬁcant (5.3 ± 0.5f o l d[ m e a n± SEM, n = 3, P<. 005])
increase in β3 phosphorylation (Figure 5(b)). Addition of
full-length TSP-1 also increased β3 phosphorylation by 2.7±
0.5f o l d[ m e a n± SEM, n = 3, P<. 005].
3.6. Glucose Regulation of TS-1 Levels in SMC. Using real-
time PCR we examined TSP-1 mRNA levels in SMC
maintained in normal versus high glucose conditions. There
was no signiﬁcant diﬀerence in the amount of TSP-1 mRNA
after24ineithernormalorhighglucosecontainingmedium.
There was more mRNA in the normal glucose culture after
48 and 72 hours. However, after 96 and 120 hours of culture,
there was more mRNA in the high glucose culture compared
with the normal glucose culture (Figure 6(a)).
We examined TSP-1 protein levels in ECM preparations
(containing equal amounts of total protein) from parallel
time-course cultures. There was a signiﬁcant increase in the
amount of TSP-1 that could be detected in the high glucose
cultures after 48 hours compared with 24 hours and this
increased further after 72 hours and remained constant at 96
and 120 hours of culture. TSP-1 protein also accumulated in
the ECM of SMC maintained in normal glucose over time
but there was signiﬁcantly less TSP-1 at each time point
compared with the amount of TSP-1 in the high glucose
cultures (Figure 6(b)).
3.7. TSP-1 Is Degraded More Rapidly in Normal Glucose SMC
Cultures. Since the changes in TSP-1 protein over time in
culture did not exactly parallel the changes in mRNA over
the same time period in the two diﬀerent culture conditions
we considered whether there was a diﬀerence in TSP-1
degradation.
In the presence of Baﬁlomycin A, an inhibitor that
raises the pH of lysosomes, thereby inhibiting the activity of
lysosomal enzymes, there was a signiﬁcant increase in TSP-
1 protein in SMC cultured in normal glucose (Figure 6(a)).
In the presence of a speciﬁc Cathepsin L inhibitor there
was a signiﬁcant increase in the amount of TSP-1 protein
that could be detected in the ECM of SMC cultured in
normal glucose (Figure 6(b)). Consistent with the diﬀerence
in TSP-1 levels between high and normal glucose culturesExperimental Diabetes Research 5
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Figure 2: The IAP binding domain of TSP-1 increases IGF-I signaling in normal glucose. (a) SMCs were grown to conﬂuency in DMEM
containing 5mM glucose and then incubated overnight in SFM with 5mM glucose. The following day the incubation was continued for 6
hours with (+) 4N1K or 4NG1G (1μg/mL). Equal amounts of lysate were then subjected to immunoprecipitation (IP) with and anti-SHPS-
1 antibody prior to immunoblotting (IB) with an anti-IAP antibody or immunoblotted directly with an anti-SHPS-1 antibody. The graph
shows the results from three similar experiments expressed as arbitrary scanning units (∗∗∗P<. 005 when the amount of IAP associated
with SHPS-1 is compared with the value for SMC incubated in 5mM glucose containing medium). (b) SMCs were grown to conﬂuency in
DMEMcontaining5mMglucose andthenincubated overnightinSFMwith5mMglucose. Thefollowingdaytheincubationwas continued
for 6 hours with (+) 4N1K or 4NG1G (1μg/mL) followed by IGF-I (50ng/mL) for 5 minutes. Equal amounts of lysate were then subjected to
immunoprecipitation (IP) with and anti-SHPS-1 antibody prior to immunoblotting (IB) with either an antiphosphotyrosine (p-Tyr) or Shc
antibody or immunoblotted directly with an anti-SHPS-1 antibody. The graph shows the results from three similar experiments expressed
as fold increase in response to IGF-I compared with no addition of peptide (∗∗∗P<. 005). (c) SMCs were grown to conﬂuency in DMEM
containing 5mM glucose and then incubated overnight in SFM with 5mM glucose. The following day the incubation was continued for
6 hours with (+) 4N1K or 4NG1G (1μg/mL) followed by IGF-I (50ng/mL) for 5 minutes. Equal amounts of lysate were then subjected to
immunoblotting (IB) with either an anti-phosphoERK or total-ERK antibody. The graph shows the results from three similar experiments
expressed as fold increase in response to IGF-I compared with no addition of peptide (∗∗∗P<. 005).
being due to a diﬀerence in TSP-1 degradation there was
no signiﬁcant increase in TSP-1 protein levels in SMC in
high glucose in the presence of the Cathepsin-L inhibitor
(Figure 7(c)).
In the presence of this inhibitor, there was a signiﬁcant
increase in the amount of CD47/IAP that could be detected,
equivalent to that detected in high glucose (Figure 7(d)).
Similarly, the increase in IAP association with SHPS-1 in
the presence of Cathepsin L inhibitor was equal to the
level of CD47/IAP association with SHPS-1 in high glucose
conditions (Figure 7(e)).
4. Discussion
Our previous studies in vitro [6], conﬁrmed in vivo [9], have
determined that the decrease in CD47/IAP cleavage is a key
aspect of the response of SMC to IGF-I in hyperglycemic6 Experimental Diabetes Research
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Figure 3: TSP-1 protein levels regulate the response of SMC to hyperglycemia. (a) SMCs expressing either the TSP-1 or a scrambled (Scr)
RNAi construct were grown to conﬂuency in DMEM containing 25mM glucose and then incubated overnight in SFM with 25mM. Equal
amounts of lysates were either subject to immunoprecipitation (IP) followed by immunoblotting or immunoblotted (IB) directly with
the antibody indicated. The graph shows the mean fold decrease of each protein in the RNAi cultures compared with the Scr control of
three independent experiments, (∗∗∗P<. 005). (b) SMC expressing either the TSP-1 or a scrambled (Scr) RNAi construct were grown to
conﬂuency in DMEM containing 25mM glucose and then incubated overnight in SFM with 25mM prior to exposure to IGF-I (50ng/mL)
for 5 minutes (+). Equal amounts of lysates were then subject to immunoprecipitation (IP) followed by immunoblotting (IB) with the
antibody indicated. The graph shows the mean fold increase in phosphorylation of each protein in response to IGF-I (∗∗∗P<. 005 when the
extent of phosphorylation in the absence of IGF-I is compared to the addition of IGF-I). (c) SMC expressing either the TSP-1 or a scrambled
(Scr) RNAi construct were grown to conﬂuency in DMEM containing 25mM glucose and then incubated overnight in SFM with 25mM
prior to exposure to IGF-I (50ng/mL) for 5 minutes (+). Equal amounts of lysates were then subject to immunoblotting (IB) with either an
antiphospho or total ERK antibody. The graph shows the mean fold increase in phosphorylation in response to IGF-I (∗∗∗P<. 005 when
the extent of phosphorylation in the absence of IGF-I is compared to the addition of IGF-I).Experimental Diabetes Research 7
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Figure 4: Restoration of the IGF-I response by addition of the CD47/IAP binding domain of TSP-1. (a) SMCs expressing either the TSP-1
or a scrambled (Scr) RNAi construct were grown to conﬂuency in DMEM containing 25mM glucose and then incubated overnight in SFM
with 25mM glucose. After overnight incubation in SFM cells were incubated for 6 hours with 4N1K (1μg/mL) prior to lysis. The amount of
intact IAP in each lysate was determined by immunoblotting with the anti-IAP antibody speciﬁc for intact IAP and the association between
IAP and SHPS-1 was determined by coimmunoprecipitation. The graphs shows the results derived from western immunoblots from three
similar experiments expressed as arbitrary scanning units increase (∗∗∗P<. 005 when the amount in the TSP-1 lysate is compared with the
Scr cell lysate). (b) SMCs expressing the TSP-1 RNAi construct were grown to conﬂuency in DMEM containing 25mM glucose and then
incubated overnight in SFM with 25mM glucose. After overnight incubation in SFM cells were incubated for 6 hours with 4N1K (1μg/mL)
then treated with IGF-I (+) where indicted for 5 minutes prior to lysis. SHPS-1 and Shc phosphorylation in equal amounts of cell lysate
was determined by immunoprecipitation and immunoblotting with an antiphosphotyrosine antibody (PY99). The graphs shows the results
derived from western immunoblots from three similar experiments expressed as fold increase in phosphorylation after treatment with IGF-I
(∗∗∗P<. 005 when the phosphorylation in the presence of 4N1K is compared with the absence). (c) 2 × 104 cells grown 25mM were plated
in each well of a 24 well plate prior to exposure to 4N1K (1μg/mL) and IGF-I (100ng/mL) in DMEM + 0.2% platelet poor plasma. 48 hours
after the addition of IGF-I cell number was determined by trypan blue staining and counting. ∗∗∗P<. 005 when cell number in response to
IGF-I is compared with control.8 Experimental Diabetes Research
IP: β3/IB: p-Tyr
IP: β3/IB: Vn
IP: β3/IB: IAP
IB: β3
0
25
50
75
100
D
e
c
r
e
a
s
e
v
e
r
s
u
s
S
c
r
(
%
)
∗∗∗
∗∗∗
IB: p-Tyr IB: IAP
IP: β3
IB: Vn
TSP-1 RNAi Scr TSP-1 RNAi
25mM glucose
(a)
IP: β3/IB: p-Tyr
IB: β3
4N1K
4NGG
−
−
−
+
+
−
25mM glucose
(b)
TSP-1 0 0.51 μg/mL
IP: β3/IB: p-Tyr
IB: β3
25mM glucose
(c)
Figure 5: TSP-1 protein levels regulate β3 phosphorylation. SMCs expressing the TSP-1 or a scrambled (Scr) RNAi construct were grown to
conﬂuency in DMEM containing 25mM glucose and then incubated overnight in SFM with 25mM glucose prior to treatment with 4N1K
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conditions. Using RNAi to reduce TSP-1 protein levels and
a peptide homologous to the CD47/IAP binding site of TSP-
1 we were able to demonstrate that the enhancing eﬀect
of hyperglycemia on IGF-I signaling was mediated by TSP-
1 binding to CD47/IAP. Thus, the increase in CD47/IAP
induced by the presence of TSP-1 leading to an increase in
CD47IAP association with SHPS-1 is a potential mechanism
to explain the increase in SMC proliferation and migration
associated with accelerated atherosclerosis in patients with
diabetes.
The mechanism by which TSP-1 may protect CD47/IAP
from cleavage remains to be determined. One possibility
is that TSP-1 binds to and inhibits accessibility of the
CD47/IAP cleavage site. We have determined previously
that the protease responsible for IAP cleavage in normal
glucose conditions is the matrix metalloprotease (MMP)
MMP-2 [6]. An alternative explanation for the mechanism
by which TSP-1 protects IAP from cleavage is via its binding
directly to MMP-2 and regulation its activity. TSP-1 was
shown to bind to MMP-2 through its properdin-like type
1 repeats and inhibit activation of the MMP-2 zymogen
[18]. However, given that the IAP binding site peptide
alone was suﬃcient to protect CD47/IAP from cleavage,
it seems more likely that TSP-1 is protecting CD47/IAP
from cleavage by inhibiting MMP-2 access to the cleavage
site.
Sajid et al. [19] have demonstrated that after balloon
injury in baboons, there was a signiﬁcant increase in TSP-
1 in the neointima and media. This was associated with a
comparable increase in CD47/IAP. Thus it seems reasonable
to propose that increased cellular levels of TSP-1 and the
subsequent protection of IAP from cleavage are common
responses of vascular SMC to stress (e.g., mechanical injury
or hyperglycemia).
While interpretation of our ﬁnding of increased TSP-1
in the aorta homogenates is limited since the homogenates
contain a mixture of cell types, our ﬁnding of increased TSP-
1 in aorta from hyperglycemic pigs is consistent with prior
studies that detected increased levels of TSP-1 in speciﬁc
areas of the blood vessels of diabetic Zucker rats [20]. Other
modelsofdiabeteshavealsodemonstratedincreasesinTSP-1
in cardiac ﬁbroblasts [21], myocytes [22, 23], and SMC [24].
Protein levels of TSP-1 are controlled at the level of RNA
synthesis and stability [24, 25]. Direct stimulation of aortic
smooth muscle cells with high glucose was shown to result in
the transcriptional activation of the thrombospondin gene
[20, 24, 25]. Our data in which TSP-1 mRNA was studied
over a period of 5 days did not show a pattern of RNA
changes that reﬂected the pattern of TSP-1 protein increase.
It is interesting to note that in several previous studies
[20, 24] SMC were transferred from 5mM glucose acutely
to 30mM glucose and this experimental paradigm may haveExperimental Diabetes Research 9
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Figure 6: Glucose regulation of TSP-1 mRNA and protein. (a) RNA prepared from whole cell lysates. One microgram of total RNA was
reverse transcribed. Two μL of the cDNA was use in a RT-PCR reaction. A standard curve was generated using the 24 hour normal glucose
sample (10-fold dilutions from 1 to 10,000). The amount of RNA is expressed relative to the level in the 24 hour normal glucose sample. (b)
AnequalnumberofSMCswereplatedingrowthmediumcontaining5or25mMglucose.Extracellularmatrixandcelllysateswereprepared
fromparallelculturesafter24,48,72,96,and120hoursandequalamountsofproteinwereseparatedbySDS-PAGEandimmunoblottedwith
the appropriate antibody. The graph show the results expressed as arbitrary scanning units, of three independent experiments. ∗∗∗P<. 005
when the level of TSP-1 protein at each time point is compared with the level at 24 hours.
inﬂuenced the results obtained and may explain why we
obtained a diﬀerent pattern.
Using inhibitors of lysosomal degradation we were able
to restore TSP-1 in normal glucose to that seen in high
glucose whereas we did not detect a signiﬁcant increase in
TSP-1 protein levels in high glucose cultures treated in a
similar manner. This suggests that a signiﬁcant contributor
t ot h ei n c r e a s ei nT S P - 1p r o t e i nl e v e l si nh y p e r g l y c e m i c
conditions is due to its protection from lysosomal degra-
dation. To our knowledge this is the ﬁrst report of glucose
mediated regulation of TSP-1 protein stability. In addition
to the regulation of TSP-1 mRNA it has also been shown
to be regulated by its rapid internalization by the endocytic
receptorLRP-1(lowdensitylipoprotein-relatedprotein)that
leads to its degradation [26–28]. Other studies have also
shown that LRP-1 levels are decreased in the aortic arch in
diabetic hamsters [29] and also in the blood brain barrier
of streptozotocin induced diabetic rats [30]. However, the
mechanism by which glucose regulates LRP-1 has not been
elucidated. If, in future studies, we can verify that LRP-1
mediates TSP-1 uptake in SMC and that this is modiﬁed
by hyperglycemia we will be able to determine whether it is
the levels of the receptor that diﬀer between normal and high
gl uc oseorsomeotherdiﬀerencethataccountsforthechange
in TSP-1 uptake and more precisely deﬁne the mechanism by
which glucose regulates TSP-1 uptake and degradation.
Several biochemical pathways have been associated with
hyperglycemia including diacylglycerol production, and the
subsequentactivationoftheproteinkinaseC(PKC)pathway,
ﬂux through the polyol metabolic pathway, accumulation
of advanced glycation end products (AGE) and cytokine
secretion [31]. The production of excess reactive oxygen
species has been suggested to be the causal link between
hyperglycemia and these changes [31]. Since, at this point
we do not know the receptor that mediates TSP-1 uptake
it is diﬃcult to predict which speciﬁc glucose mediated
event reduces TSP-1 uptake in SMC. Interestingly however,
it has been shown in cells from glioblastoma tumors that
activation of PKC (alpha) resulted in the down-regulated
LRP [32], suggesting a possible relationship between the
activation of the PKC pathway, down-regulation of LRP
and thus decreased cellular uptake of TSP-1. Additionally,
it has been shown that there are changes in the relative
distribution of the receptor for advanced glycation end10 Experimental Diabetes Research
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Figure 7: TSP-1 degradation. (a)–(e) SMCs grown to conﬂuency in medium containing 25 or 5mM glucose were incubated overnight in
SFM and then treated with (+) a cathepsin inhibitor (100nM), (+) baﬁlomycin (100nM) or vehicle (−)f o r6h o u r sp r i o rt oe x t r a c e l l u l a r
matrix preparation and immunoblotting with the anti-TSP-1 antibody or cell lysis/immunoprecipitation with the antibodies indicated. The
graphs show the results of arbitrary scanning units derived from the western immunoblots of three independent experiments. Vertical line
indicates where discontinuous bands from the same gel were used.
products (RAGE) and LRP in the blood brain barrier
of the human hippocampus of patients with Alzheimer’s
disease; as levels of RAGE increase then levels of LRP
are decreased [33]. While merely speculative these ﬁndings
provide potential directions to pursue that may ultimately
shed light on the precise mechanism by which TSP-1 cellular
uptake and degradation are reduced in SMC maintained in
hyperglycemia.
CD47/IAP was identiﬁed through its association with
αVβ3[ 16]. Furthermore, CD47/IAP binding to αVβ3h a s
been shown to increase integrin clustering [34]. Importantly,
the extracellular domain of CD47/IAP, which is the region
of CD47/IAP that is lost during cleavage, is critical for
its ability to induce αVβ3 clustering [34]. TSP-1 binding
to CD47/IAP has been implicated in stimulating a high
aﬃnity state in αIIbβ3 leading to activation of the integrin
and platelet spreading, stimulation of platelet aggregation
[35, 36]. Our study suggests that the TSP-1 increase in
CD47/IAP plays a dual role in regulating the response of
SMC to IGF-I in hyperglycemic conditions. In addition to
increasing CD47/IAP association with SHPS-1 it also reg-
ulates CD47/IAP association with αVβ3 thereby regulating
the activation status of the integrin, reﬂected in β3 phos-
phorylation. We have shown previously, by expressing β3i n
whichbothtyrosineresiduesinthecytoplasmicdomainwere
mutated to phenylalanine, that the phosphorylation of β3i s
required for its positive eﬀect on IGF-I signaling [17].
The results from this study demonstrate that glucose
regulation of TSP-1, by reducing its lysosomal degradation,
enhances IGF-I signaling in SMC by protecting CD47/IAPExperimental Diabetes Research 11
from cleavage thereby increasing its association with its lig-
andsSHPS-1andαVβ3.Theseresultssupportthehypothesis
that the glucose stimulated increase in TSP-1 may play an
important role in the accelerated atherosclerosis associated
with diabetes and identifying the receptors that mediate
the eﬀects of TSP-1 is a potential strategy to prevent the
initiation and development of atherosclerotic lesions in these
patients.
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